Patrick J Morris

List of Publications by Year
in descending order

34 papers	4,193 citations	279798 23 h-index	361022 35 g-index
39 all docs	39 docs citations	39 times ranked	5477 citing authors

#	Article	IF	Citations
1	NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature, 2016, 533, 481-486.	27.8	1,246
2	Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews, 2018, 70, 621-660.	16.0	723
3	Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature, 2017, 549, 533-537.	27.8	350
4	Palladiumâ€Catalyzed Diastereoâ€•and Enantioselective Synthesis of Substituted Cyclopentanes through a Dynamic Kinetic Asymmetric Formal [3+2]â€Cycloaddition of Vinyl Cyclopropanes and Alkylidene Azlactones. Angewandte Chemie - International Edition, 2011, 50, 6167-6170.	13.8	207
5	Palladium-Catalyzed Diastereo- and Enantioselective Formal [3 + 2]-Cycloadditions of Substituted Vinylcyclopropanes. Journal of the American Chemical Society, 2012, 134, 17823-17831.	13.7	170
6	Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability. Molecular Psychiatry, 2021, 26, 6704-6722.	7.9	139
7	Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Science Translational Medicine, 2019, 11, .	12.4	129
8	High-potency ligands for DREADD imaging and activation in rodents and monkeys. Nature Communications, 2019, 10, 4627.	12.8	128
9	Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T Sciences of the United States of America, 2019, 116, 5160-5169.	7.1	120
10	(2R,6R)-hydroxynorketamine exerts mGlu ₂ receptor-dependent antidepressant actions. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 6441-6450.	7.1	112
11	The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. PLoS Neglected Tropical Diseases, 2017, 11, e0005540.	3.0	97
12	Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects. Psychopharmacology, 2018, 235, 3017-3030.	3.1	81
13	Organophosphorus Flame Retardants Inhibit Specific Liver Carboxylesterases and Cause Serum Hypertriglyceridemia. ACS Chemical Biology, 2014, 9, 1097-1103.	3.4	76
14	Synthesis and N-Methyl-<scp>d</scp>-aspartate (NMDA) Receptor Activity of Ketamine Metabolites. Organic Letters, 2017, 19, 4572-4575.	4.6	64
15	(R)â€Ketamine exerts antidepressant actions partly via conversion to (2R,6R)â€hydroxynorketamine, while causing adverse effects at subâ€anaesthetic doses. British Journal of Pharmacology, 2019, 176, 2573-2592.	5.4	61
16	Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications. Pharmacological Reviews, 2021, 73, 763-791.	16.0	54
17	Identification of Combinations of Approved Drugs With Synergistic Activity Against Ebola Virus in Cell Cultures. Journal of Infectious Diseases, 2018, 218, S672-S678.	4.0	49
18	Metabolic Profiling Reveals PAFAH1B3 as a Critical Driver of Breast Cancer Pathogenicity. Chemistry and Biology, 2014, 21, 831-840.	6.0	44

#	Article	IF	Citations
19	Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of (2R,6R)-hydroxynorketamine. Journal of Psychopharmacology, 2019, 33, 12-24.	4.0	41
20	Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 1203-1207.	2.8	39
21	Multidimensional Profiling Platforms Reveal Metabolic Dysregulation Caused by Organophosphorus Pesticides. ACS Chemical Biology, 2014, 9, 423-432.	3.4	31
22	Zanos et al. reply. Nature, 2017, 546, E4-E5.	27.8	29
23	Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. Biological Psychiatry, 2017, 81, e69-e71.	1.3	22
24	miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. Journal of Experimental Medicine, 2018, 215, 2115-2136.	8.5	20
25	A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801. Neurotoxicology and Teratology, 2021, 87, 106993.	2.4	15
26	Hydroxynorketamine Pharmacokinetics and Antidepressant Behavioral Effects of (2,6)- and (5R)-Methyl-(2R,6R)-hydroxynorketamines. ACS Chemical Neuroscience, 2022, 13, 510-523.	3.5	15
27	Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search. Molecular Psychiatry, 2022, 27, 4144-4156.	7.9	15
28	Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo. Microorganisms, 2021, 9, 566.	3.6	13
29	Chemical Genetics Screening Reveals KIAA1363 as a Cytokine-Lowering Target. ACS Chemical Biology, 2014, 9, 2905-2913.	3.4	9
30	Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration. Translational Psychiatry, 2022, 12, 179.	4.8	8
31	18F-labeled radiotracers for inÂvivo imaging of DREADD with positron emission tomography. European Journal of Medicinal Chemistry, 2021, 213, 113047.	5.5	7
32	Apilimod. IUCrData, 2017, 2, .	0.3	4
33	Time will tell. Reply to â€œComments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.â€•by Chen et al.. Molecular Psychiatry, 2022, 27, 1863-1865.	7.9	3
34	The show must go on. Reply to â€œDistinct functions of S-ketamine and R-ketamine in mediating biobehavioral processes of drug dependency: comments on Bonaventura et alâ€•by Insop Shim. Molecular Psychiatry, 0, , .	7.9	0